The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Contribution Of Ovarian Cancer Stem Cells To Chemoresistance And Recurrent Disease.
Funder
National Health and Medical Research Council
Funding Amount
$378,940.00
Summary
Ovarian cancer is the most lethal gynaecological cancer. Previously, we showed that cancer stem cells are the “beating heart” of the ovarian cancer and are responsible for drug resistance and tumour relapse. The ineffective targeting of these cells by chemotherapy is accountable for the poor clinical outcomes in ovarian cancer patients. This project will define the molecular signals involved in maintenance of cancer stem cells and develop targeted therapies against these cells.
CHARACTERIZATION OF A NEW SUBTYPE OF AGGRESSIVE BREAST CANCER
Funder
National Health and Medical Research Council
Funding Amount
$763,152.00
Summary
Much effort has been invested in the sequencing of cancer genomes, leading to the identification of genes linked to aggressive subtypes. There is now a need to confirm the importance of these genes and to exploit these findings for patient therapies. We have identified a new cancer driver controlling an aggressive type of breast tumour which may act through one carbon/folate metabolism. We aim to map the inner workings of these cancers to devise effective targeted drugs for these patients.
Developing Irreversible Electroporation Non-Thermal Tumor Ablation For Organ-Confined Prostate Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$290,512.00
Summary
IRE is technique for targeted tissue ablation. Electrodes placed into the targeted area deliver intense, brief electric pulses. Nano-scale pores are created in the cell membrane killing the cells but preserving the extracellular matrix. The pulses do not affect sensitive structures including neurovascular bundles, major vasculature and ductal systems preserving their function. It may address prostate regions implicated in prostate cancer without damaging vital structures, reducing side effects.
Osteosarcoma is the most common tumour of bone. Recent success in targeting immune checkpoint blockers such as Programmed death-1 (PD-1) in genomically complex tumours suggests that osteosarcomas may be amenable to such strategies. We will characterise the role of the PD-1 pathway in osteosarcoma development and growth. Using preclinical mouse models we will investigate the biology of the PD-1 pathway and study its potential as a therapeutic target in advanced and resectable osteosarcoma.
Use of antibodies for cancer therapy, where a protein is made in the laboratory to recognize and act on cancer cells that have a target antigen, has emerged as an important therapeutic area in oncology. The lewis-y (Ley) antigen is found on more than 70% of epithelial cancers and the A33 antigen is found on colon cancers. We have developed antibodies against Ley (hu3S193) and A33 (huA33) which can target cancer cells. We aim to develop optimal cancer cell killing by our antibodies.
Nanomedicines Immunotargeting: Hitting The Target Or Lost In Translation ?
Funder
National Health and Medical Research Council
Funding Amount
$413,042.00
Summary
Nanomedicines are some of the most exciting novel approaches to improving the way we detect, manage and treat cancers. This cross-disciplinary project aims to provide a rigorous understanding of how nanomedicines penetrate solid tumour tissues. To validate in vitro tumour model developed in the project, in vivo studies will be carried out in a mice model. The penetration and distribution of nanomedicines inside tumour tissues after intravenous administration will be determined.
Microtubule Cytoskeleton In Tumourigenesis And Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$612,885.00
Summary
Over one million cases of lung cancer are diagnosed each year worldwide, making this the leading cause of cancer death. Advanced non-small cell lung cancer (NSCLC) accounts for more than 80% of lung cancer cases. We have identified a protein called ?III-tubulin that is often highly expressed in aggressive and drug resistant NSCLC, and is involved in tumour formation. We will examine how ?III-tubulin is working and identify ways to target this protein to stop tumour growth.
A 2:1 Randomised Phase II Study Of NivolUmab And Temozolomide Vs Temozolomide In Methylated Newly Diagnosed Elderly Glioblastoma (NUTMEG)
Funder
National Health and Medical Research Council
Funding Amount
$1,608,845.00
Summary
Radiotherapy and Temozolomide (TMZ) chemotherapy treatment for the brain tumour glioblastoma (GBM) is not as effective in elderly patients. If their tumour has a genetic marker called "methylated MGMT", TMZ does work relatively better and is often given alone. Elderly GBM patients with this marker will be randomly selected in this trial to have TMZ alone or TMZ + Nivolumab - a drug that assists the immune system to attack cancer.
Targeting Mitochondrial Metabolism In Diffuse Intrinsic Pontine Gliomas As A Novel Therapeutic Strategy
Funder
National Health and Medical Research Council
Funding Amount
$607,796.00
Summary
Diffuse Intrinsic Pontine Glioma (DIPG) represents the most aggressive cancer of childhood, with no effective treatments available, and almost all children dying within one year of diagnosis. We have successfully grown the first DIPG cells in the laboratory and found a new approach to attack them, by specifically targeting the cell's power source - the mitochondria. We will build on these findings and develop this treatment strategy with the aim to make this novel therapy available to children w ....Diffuse Intrinsic Pontine Glioma (DIPG) represents the most aggressive cancer of childhood, with no effective treatments available, and almost all children dying within one year of diagnosis. We have successfully grown the first DIPG cells in the laboratory and found a new approach to attack them, by specifically targeting the cell's power source - the mitochondria. We will build on these findings and develop this treatment strategy with the aim to make this novel therapy available to children with this deadly disease.Read moreRead less
Nfib Regulates Glial Differentiation During Development And Disease Via Repression Of The Key Epigenetic Protein, Ezh2
Funder
National Health and Medical Research Council
Funding Amount
$572,912.00
Summary
Glial development is critical during development, and unrestrained proliferation of glial stem cells in the adult can lead to deadly brain cancers such as glioma. At present there is no cure for glioma and current treatments do not significantly delay tumour progression. Nfib is a transcription factor that may prevent tumour growth through cellular differentiation. We will investigate the role of Nfib during development and in the pathogenesis of glioma and its potential as a therapeutic target.